Trial
NCT02123966
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
—
Condition
Chronic Graft-versus-Host-Disease
Intervention
Sirolimus
Why stopped
Due to slow accrual, study team has decided to end the study early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-07-24